Search

Your search keyword '"Copelan, Edward A."' showing total 1,172 results
Start Over Author "Copelan, Edward A."
1,172 results on '"Copelan, Edward A."'

102. Upper respiratory tract SARS-CoV-2 viral shedding in cancer patients.

Author

Shahid, Zainab, primary, Baldrige, Emily, additional, Trufan, Sally, additional, Schepel, Courtney, additional, Tan, Antoinette R., additional, Hwang, Jimmy J., additional, Musselwhite, Laura W., additional, Chai, Seungjean, additional, Sumrall, Ashley Love, additional, Ragon, Brittany K., additional, Voorhees, Peter Michael, additional, Grunwald, Michael Richard, additional, Ghosh, Nilanjan, additional, Usmani, Saad Zafar, additional, Copelan, Edward Alan, additional, Raghavan, Derek, additional, and Mileham, Kathryn Finch, additional

Published
2021
Full Text
View/download PDF

103. Risk factors for hospitalization for cancer patients with SARS-CoV-2 infection.

Author

Shahid, Zainab, primary, Baldrige, Emily, additional, Trufan, Sally, additional, Schepel, Courtney, additional, Tan, Antoinette R., additional, Hwang, Jimmy J., additional, Musselwhite, Laura W., additional, Kim, Edward S., additional, Chai, Seungjean, additional, Sumrall, Ashley Love, additional, Ragon, Brittany K., additional, Voorhees, Peter Michael, additional, Grunwald, Michael Richard, additional, Ghosh, Nilanjan, additional, Usmani, Saad Zafar, additional, Copelan, Edward Alan, additional, and Raghavan, Derek, additional

Published
2021
Full Text
View/download PDF

104. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author

Jimenez, Antonio M. Jimenez, De Lima, Marcos, Komanduri, Krishna, V, Wang, Trent P., Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Diaz Perez, Miguel Angel, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R., Hildebrandt, Gerhard C., Hogan, William J., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Krem, Maxwell M., Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios, V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F., Wirk, Baldeep, Yared, Jean A., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, Weisdorf, Daniel, Jimenez, Antonio M. Jimenez, De Lima, Marcos, Komanduri, Krishna, V, Wang, Trent P., Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Diaz Perez, Miguel Angel, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R., Hildebrandt, Gerhard C., Hogan, William J., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Krem, Maxwell M., Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios, V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F., Wirk, Baldeep, Yared, Jean A., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, and Weisdorf, Daniel

Abstract

Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p < 0.001); disease-free survival (DFS) (Fav: 57.8%, IM: 55.5% and Adv: 45.3; p < 0.001) and relapse (Fav: 28%, IM: 27.5% and Adv: 37.5%; p < 0.001). Multivariate analysis (MVA) revealed no differences in outcomes between the Fav and IM groups, thus they were combined. On MVA, patients in the Adv risk group had the highest risk of relapse (HR 1.47 p <= 0.001) and inferior DFS (HR 1.35 p < 0.001) and OS (HR 1.39 p < 0.001), even using myeloablative conditioning or in those without the pre-HCT measurable-residual disease. Novel approaches to mitigate relapse in this high-risk group are urgently needed.

Published
2021
Full Text
View/download PDF

105. Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Author

Jimenez, Antonio M., Wang, Trent, de Lima, Marcos, Komanduri, Krishna V, Kebriaei, Partow, Litzow, Mark, Bhatt, Vijaya Raj, Baron, Frédéric, Saad, Ayman, Khera, Nandita, Maakaron, Joseph, Murthy, Hemant S., Copelan, Edward A, Defilipp, Zachariah, Bredeson, Christopher, Martino, Rodrigo, Krem, Maxwell, Nishihori, Taiga, Zhang, Mei-Jie, Weisdorf, Daniel J., Chen, Karen, and Saber, Wael

Published
2020
Full Text
View/download PDF

106. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Author

Lee, Stephanie J., Kukreja, Manisha, Wang, Tao, Giralt, Sergio A., Szer, Jeffrey, Arora, Mukta, Woolfrey, Ann E., Cervantes, Francisco, Champlin, Richard E., Gale, Robert Peter, Halter, Joerg, Keating, Armand, Marks, David I., McCarthy, Philip L., Olavarria, Eduardo, Stadtmauer, Edward A., Abecasis, Manuel, Gupta, Vikas, Khoury, H. Jean, George, Biju, Hale, Gregory A., Liesveld, Jane L., Rizzieri, David A., Antin, Joseph H., Bolwell, Brian J., Carabasi, Matthew H., Copelan, Edward, Ilhan, Osman, Litzow, Mark R., Schouten, Harold C., Zander, Axel R., Horowitz, Mary M., and Maziarz, Richard T.

Published
2008
Full Text
View/download PDF

107. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission

Author

Marks, David I., Pérez, Waleska S., He, Wensheng, Zhang, Mei-Jie, Bishop, Michael R., Bolwell, Brian J., Bredeson, Christopher N., Copelan, Edward A., Gale, Robert Peter, Gupta, Vikas, Hale, Gregory A., Isola, Luis M., Jakubowski, Ann A., Keating, Armand, Klumpp, Thomas R., Lazarus, Hillard M., Liesveld, Jane L., Maziarz, Richard T., McCarthy, Philip L., Sabloff, Mitchell, Schiller, Gary, Sierra, Jorge, Tallman, Martin S., Waller, Edmund K., Wiernik, Peter H., and Weisdorf, Daniel J.

Published
2008
Full Text
View/download PDF

110. HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR

Author

Schlenk, Richard F., Pasquini, Marcelo C., Pérez, Waleska S., Zhang, Mei-Jie, Krauter, Jürgen, Antin, Joseph H., Bashey, Asad, Bolwell, Brian J., Büchner, Thomas, Cahn, Jean-Yves, Cairo, Mitchell S., Copelan, Edward A., Cutler, Corey S., Döhner, Hartmut, Gale, Robert Peter, Ilhan, Osman, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Nimer, Stephen D., Sierra, Jorge, Tallman, Martin S., Weisdorf, Daniel J., Horowitz, Mary M., and Ganser, Arnold

Published
2008
Full Text
View/download PDF

114. Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation

Author

Sanikommu, Srinivasa Reddy, primary, Reese, Emily S., additional, He, Jiaxian, additional, Lee, Carlos, additional, Ai, Jing, additional, Butler, Candace M., additional, Jacobs, Ryan, additional, Hu, Bei, additional, Atrash, Shebli, additional, Trivedi, Jigar, additional, Bhutani, Manisha, additional, Voorhees, Peter, additional, Usmani, Saad Z., additional, Ghosh, Nilanjan, additional, Fasan, Omotayo, additional, Druhan, Lawrence J., additional, Symanowski, James, additional, Copelan, Edward A., additional, and Avalos, Belinda R., additional

Published
2021
Full Text
View/download PDF

115. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

Author

Hamadeh, Issam S., primary, Grunwald, Michael R., additional, Martin, Allison, additional, Patel, Jai N., additional, Wolff, Alexandra, additional, Kachur, Ekaterina, additional, Cook, Allene, additional, Karabinos, Allison, additional, Ai, Jing, additional, Knight, Thomas G., additional, Ragon, Brittany, additional, Chojecki, Aleksander L., additional, Shah, Nilay A, additional, Sanikommu, Srinivasa Reddy, additional, Copelan, Edward A., additional, Avalos, Belinda R., additional, and Shahid, Zainab, additional

Published
2021
Full Text
View/download PDF

116. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy

Author

Epperla, Narendranath, Li, Ang, Logan, Brent, Fretham, Caitrin, Chhabra, Saurabh, Aljurf, Mahmoud, Chee, Lynette, Copelan, Edward, Freytes, Cesar O., Hematti, Peiman, Lazarus, Hillard M., Litzow, Mark, Nishihori, Taiga, Olsson, Richard, Prestidge, Tim, Saber, Wael, Wirk, Baldeep, Yared, Jean A., Loren, Alison, Pasquini, Marcelo, Epperla, Narendranath, Li, Ang, Logan, Brent, Fretham, Caitrin, Chhabra, Saurabh, Aljurf, Mahmoud, Chee, Lynette, Copelan, Edward, Freytes, Cesar O., Hematti, Peiman, Lazarus, Hillard M., Litzow, Mark, Nishihori, Taiga, Olsson, Richard, Prestidge, Tim, Saber, Wael, Wirk, Baldeep, Yared, Jean A., Loren, Alison, and Pasquini, Marcelo

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic transplantation (allo-HCT). The incidence and risk factors associated with TA-TMA are not well known. A retrospective analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) was conducted including patients receiving allo-HCT between 2008 and 2016, with the primary objective of evaluating the incidence of TA-TMA. Secondary objectives included identification of risk factors associated with TA-TMA, and the impact of TA-TMA on overall survival and the need for renal replacement therapy (RRT). Among 23,665 allo-HCT recipients, the 3-year cumulative incidence of TA-TMA was 3%. Variables independently-associated with increased incidence of TA-TMA included female sex, prior autologous transplant, primary disease (acute lymphoblastic leukaemia and severe aplastic anaemia), donor type (mismatched or unrelated donor), conditioning intensity (myeloablative), GVHD prophylaxis (sirolimus + calcineurin inhibitor), pre-transplant kidney dysfunction and acute GVHD (time-varying effect). TA-TMA was associated with higher mortality (HR = 3 center dot 1, 95% Confidence Interval [CI] = 2 center dot 8-16 center dot 3) and RRT requirement (HR = 7 center dot 1, 95% CI = 5 center dot 7-311 center dot 6). This study provides epidemiologic data on TA-TMA and its impact on transplant outcomes. Increased awareness of the risk factors will enable providers to be vigilant of this uncommon but serious transplant complication. The results will also provide benchmarking for future study designs and comparisons.

Published
2020
Full Text
View/download PDF

117. Age no bar : A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

Author

Munshi, Pashna N., Vesole, David, Jurczyszyn, Artur, Zaucha, Jan Maciej, St Martin, Andrew, Davila, Omar, Agrawal, Vaibhav, Badawy, Sherif M., Battiwalla, Minoo, Chhabra, Saurabh, Copelan, Edward, Kharfan-Dabaja, Mohamed A., Farhadfar, Nosha, Ganguly, Siddhartha, Hashmi, Shahrukh, Krem, Maxwell M., Lazarus, Hillard M., Malek, Ehsan, Meehan, Kenneth, Murthy, Hemant S., Nishihori, Taiga, Olin, Rebecca L., Olsson, Richard F., Schriber, Jeffrey, Seo, Sachiko, Shah, Gunjan, Solh, Melhem, Tay, Jason, Kumar, Shaji, Qazilbash, Muzaffar H., Shah, Nina, Hari, Parameswaran N., D'Souza, Anita, Munshi, Pashna N., Vesole, David, Jurczyszyn, Artur, Zaucha, Jan Maciej, St Martin, Andrew, Davila, Omar, Agrawal, Vaibhav, Badawy, Sherif M., Battiwalla, Minoo, Chhabra, Saurabh, Copelan, Edward, Kharfan-Dabaja, Mohamed A., Farhadfar, Nosha, Ganguly, Siddhartha, Hashmi, Shahrukh, Krem, Maxwell M., Lazarus, Hillard M., Malek, Ehsan, Meehan, Kenneth, Murthy, Hemant S., Nishihori, Taiga, Olin, Rebecca L., Olsson, Richard F., Schriber, Jeffrey, Seo, Sachiko, Shah, Gunjan, Solh, Melhem, Tay, Jason, Kumar, Shaji, Qazilbash, Muzaffar H., Shah, Nina, Hari, Parameswaran N., and D'Souza, Anita

Abstract

Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. Methods The authors investigated the outcomes of AHCT in patients with MM who were aged >= 70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged >= 70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, aPvalue <.01 was considered to be statistically significant a priori. Results An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged >= 70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m(2)overall, 58% of the patients aged >= 70 years received Mel at a dose of 140 mg/m(2). On multivariate analysis, patients aged >= 70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1-1.7 [P = .06]), REL (HR, 1.03; 99% CI, 0.9-1.1 [P = 0.6]), PFS (HR, 1.06; 99% CI, 1-1.2 [P = 0.2]), and OS (HR, 1.2; 99% CI, 1-1.4 [P = .02]) compared with the reference group (those aged 60-69 years). In patients aged >= 70 years, Mel administered at a dose of 140 mg/m(2)was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m(2), including day 100 NRM (1% [95% CI, 1%-2%] vs 0% [95% CI, 0%-1%];P = .003]), 2-year PFS (64% [95% CI, 60%-67%] vs 69% [95% CI, 66%-73%];P = .003), and 2-year OS (85% [95% CI, 82%-87%] vs 89% [95% CI, 86%-91%];P = .01]), likely representing frailty. Conclusions The results of the

Published
2020
Full Text
View/download PDF

121. Hematopoietic stem-cell transplantation

Author

Copelan, Edward A.

Subjects
Blood diseases -- Care and treatment, Cancer -- Care and treatment, Hematopoietic stem cells -- Transplantation, Hematopoietic stem cells -- Patient outcomes
Abstract

The role of haematopoietic stem cell transplantation in treating malignant and nonmalignant conditions is discussed. Haematopoietic stem cell transplantation can cure hematologic and lymphoid cancers, the procedure has resulted in sustained remission in patients with autoimmune disease and it has been found to cure many genetic diseases.

Published
2006

122. Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Author

Knight, Thomas G., primary, Aguiar, Melissa, additional, Robinson, Myra, additional, Martin, Allison, additional, Cranford, Heather, additional, Chen, Tommy, additional, Bose, Rupali, additional, Ai, Jing, additional, Ragon, Brittany K., additional, Chojecki, Aleksander L., additional, Shah, Nilay A., additional, Sanikommu, Srinivasa R., additional, Symanowski, James, additional, Copelan, Edward A, additional, and Grunwald, Michael R., additional

Published
2020
Full Text
View/download PDF

123. Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Author

Knight, Thomas G., primary, Aguiar, Melissa, additional, Robinson, Myra, additional, Martin, Allison, additional, Chen, Tommy, additional, Bose, Rupali, additional, Ai, Jing, additional, Ragon, Brittany K., additional, Chojecki, Aleksander L., additional, Shah, Nilay A., additional, Sanikommu, Srinivasa R., additional, Symanowski, James, additional, Copelan, Edward A, additional, and Grunwald, Michael R., additional

Published
2020
Full Text
View/download PDF

124. Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

Author

Hamadeh, Issam S., primary, Grunwald, Michael R., additional, Martin, Allison, additional, Patel, Jai N., additional, Shillingburg, Alexandra, additional, Kachur, Ekaterina, additional, COOK, Allene, additional, Karabinos, Allison, additional, Ai, Jing, additional, Knight, Thomas G., additional, Ragon, Brittany K., additional, Chojecki, Aleksander L., additional, Shah, Nilay A., additional, Sanikommu, Srinivasa R., additional, Avalos, Belinda R, additional, Copelan, Edward A, additional, and Shahid, Zainab, additional

Published
2020
Full Text
View/download PDF

125. Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia

Author

Denson, Ariel, primary, DiSogra, Kristyn Y., additional, Arnall, Justin, additional, Sanikommu, Srinivasa R., additional, Shah, Nilay A., additional, Ragon, Brittany K., additional, Knight, Thomas G., additional, Ai, Jing, additional, Grunwald, Michael R., additional, Avalos, Belinda R, additional, Copelan, Edward A, additional, and Chojecki, Aleksander L., additional

Published
2020
Full Text
View/download PDF

126. Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative

Author

Chojecki, Aleksander L., primary, DiSogra, Kristyn Y., additional, Arnall, Justin, additional, Cowgill, Nicole, additional, Sanikommu, Srinivasa Reddy, additional, Shah, Nilay A., additional, Packman, Charles H., additional, Ragon, Brittany K., additional, Knight, Thomas G., additional, Ai, Jing, additional, Avalos, Belinda R, additional, Copelan, Edward A, additional, and Grunwald, Michael R., additional

Published
2020
Full Text
View/download PDF

130. A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission

Author

Marks, David I., Forman, Stephen J., Blume, Karl G., Pérez, Waleska S., Weisdorf, Daniel J., Keating, Armand, Gale, Robert Peter, Cairo, Mitchell S., Copelan, Edward A., Horan, John T., Lazarus, Hillard M., Litzow, Mark R., McCarthy, Philip L., Schultz, Kirk R., Smith, David D., Trigg, Michael E., Zhang, Mei-Jie, and Horowitz, Mary M.

Published
2006
Full Text
View/download PDF

139. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

Author

Munshi, Pashna N., primary, Vesole, David, additional, Jurczyszyn, Artur, additional, Zaucha, Jan Maciej, additional, St. Martin, Andrew, additional, Davila, Omar, additional, Agrawal, Vaibhav, additional, Badawy, Sherif M., additional, Battiwalla, Minoo, additional, Chhabra, Saurabh, additional, Copelan, Edward, additional, Kharfan‐Dabaja, Mohamed A., additional, Farhadfar, Nosha, additional, Ganguly, Siddhartha, additional, Hashmi, Shahrukh, additional, Krem, Maxwell M., additional, Lazarus, Hillard M., additional, Malek, Ehsan, additional, Meehan, Kenneth, additional, Murthy, Hemant S., additional, Nishihori, Taiga, additional, Olin, Rebecca L., additional, Olsson, Richard F., additional, Schriber, Jeffrey, additional, Seo, Sachiko, additional, Shah, Gunjan, additional, Solh, Melhem, additional, Tay, Jason, additional, Kumar, Shaji, additional, Qazilbash, Muzaffar H., additional, Shah, Nina, additional, Hari, Parameswaran N., additional, and D’Souza, Anita, additional

Published
2020
Full Text
View/download PDF

140. Abstract 1920: Response to hypomethylating agents based on cytidine deaminase expression, genetic polymorphisms, and NPM1 mutation status in acute myeloid leukemia

Author

Ragon, Brittany Knick, primary, Hamadeh, Issam S., additional, Vestal, C Greer, additional, Hamilton, Alicia, additional, Smith, Mathew L., additional, Boselli, Danielle, additional, Ai, Jing, additional, Knight, Thomas G., additional, Grunwald, Michael R., additional, Gerber, Jonathan M., additional, Copelan, Edward A., additional, Druhan, Lawrence J., additional, Avalos, Belinda R., additional, Steuerwald, Nury M., additional, and Patel, Jai N., additional

Published
2020
Full Text
View/download PDF

143. Outcomes in minority patients (pt) with aggressive B cell lymphoma (BCL) if optimally managed with equal access to care and nurse navigation (NN).

Author

Hu, Bei, primary, Chen, Tommy, additional, Boselli, Danielle, additional, Pye, Lisa, additional, Bose, Rupali, additional, Raghavan, Derek, additional, Symanowski, James Thomas, additional, Blackley, Kris, additional, Moyo, Tamara Kay, additional, Jacobs, Ryan, additional, Park, Steven, additional, Soni, Amy, additional, Avalos, Belinda, additional, Copelan, Edward Alan, additional, and Ghosh, Nilanjan, additional

Published
2020
Full Text
View/download PDF

144. Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy

Author

Epperla, Narendranath, primary, Li, Ang, additional, Logan, Brent, additional, Fretham, Caitrin, additional, Chhabra, Saurabh, additional, Aljurf, Mahmoud, additional, Chee, Lynette, additional, Copelan, Edward, additional, Freytes, César O., additional, Hematti, Peiman, additional, Lazarus, Hillard M., additional, Litzow, Mark, additional, Nishihori, Taiga, additional, Olsson, Richard F., additional, Prestidge, Tim, additional, Saber, Wael, additional, Wirk, Baldeep, additional, Yared, Jean A., additional, Loren, Alison, additional, Pasquini, Marcelo, additional, Abraham, Allistair A., additional, Agrawal, Vaibhav, additional, Askar, Medhat, additional, Barba, Pere, additional, Bertaina, Alice, additional, Cahn, Jean‐Yves, additional, Cerny, Jan, additional, Choe, Hannah K., additional, Diaz, Miguel Angel, additional, Dvorak, Christopher, additional, Farhadfar, Nosha, additional, Gadalla, Shahinaz M., additional, Gergis, Usama, additional, Ganguly, Siddhartha, additional, Hashmi, Shahrukh, additional, Kasow, Kimberly A., additional, Nathan, Sunita, additional, Nusrat, Roomi, additional, Seo, Sachiko, additional, and Shah, Niketa C., additional

Published
2020
Full Text
View/download PDF

145. Favorable Survival Outcomes in Acute Myeloid Leukemia (AML) Patients (pts) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) without Achieving Complete Remission (CR) to Non-Intensive Chemotherapy

Author

Ai, Jing, primary, Boselli, Danielle, additional, Chen, Tommy, additional, Knight, Thomas G., additional, Ragon, Britney K., additional, Chojecki, Aleksander L., additional, Symanowski, James T., additional, Avalos, Belinda R., additional, Gerber, Jonathan M., additional, Copelan, Edward A., additional, and Grunwald, Michael R., additional

Published
2020
Full Text
View/download PDF

148. Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Author

Knight, Thomas G., primary, Robinson, Myra, additional, Ai, Jing, additional, Ragon, Brittany K, additional, Davis, Rhonda, additional, Shiflett, Cindy, additional, Ruston, Erica, additional, Glover, Hailey, additional, Trivedi, Jigar, additional, Avalos, Belinda R, additional, Gerber, Jonathan M., additional, Symanowski, James T, additional, Copelan, Edward A, additional, and Grunwald, Michael R., additional

Published
2019
Full Text
View/download PDF

149. Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Author

Grunwald, Michael R., primary, Zhang, Mei-Jie, additional, Elmariah, Hany, additional, Johnson, Mariam H, additional, St. Martin, Andrew, additional, Bashey, Asad, additional, Bolanos-Meade, Javier, additional, Bredeson, Christopher, additional, Copelan, Edward A, additional, George, Biju, additional, Gupta, Vikas, additional, Kanakry, Christopher G., additional, Mehta, Rohtesh S., additional, Battiwalla, Minoo, additional, Mussetti, Alberto, additional, Nakamura, Ryotaro, additional, Nishihori, Taiga, additional, Saber, Wael, additional, Solh, Melhem, additional, Tomlinson, Benjamin K., additional, Weisdorf, Daniel J., additional, and Eapen, Mary, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results